In a deal potentially worth $810 million for Regenxbio Inc., Nippon Shinyaku Co. Ltd. is partnering on the U.S. and Asian development and commercialization of iduronate-2-sulfatase enzyme RGX-121 for ...
Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the ...
An experimental tuberculosis (TB) vaccine with a dual mission – self-destruction after inducing immunity – improved the design of the Bacillus Calmette-Guérin (BCG) immunotherapy, a vaccine also used ...
In the Jan. 1, 2025, issue of Nature, researchers from the Allen Institute presented a map of areas and cell types where ...
The U.S. FDA’s Accreditation Scheme for Conformity Assessment (ASCA) program has its benefits, but industry had some sharp ...
In the first patenting to emerge from Carlsbad, Calif.-based Biologic Input Output Systems Inc., its chief development ...
Canary Cure’s CCT-217 demonstrates fat loss and lean body mass preservation in preclinical studies
Canary Cure Therapeutics (Canary Global Inc.) has released preclinical results for its lead candidate, CCT-217, an siRNA ...
Quanterix Corp. plans to merge with Akoya Biosciences Inc., in an all-stock transaction that both companies hope will bolster ...
Researchers from Boehringer Ingelheim Pharma GmbH & Co KG have published preclinical data for their novel pan-KRAS inhibitors ...
Insilico Medicine Inc. nabbed a potential $550 million-plus deal with Menarini Group’s Stemline Therapeutics Inc. for an unnamed preclinical small-molecule drug targeting solid tumors, adding to a ...
Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to ...
Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback